Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2026-02-24 @ 12:42 PM
Study NCT ID:
NCT00114920
Status:
COMPLETED
Last Update Posted:
2007-02-19
First Post:
2005-06-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014860', 'term': 'Warts'}], 'ancestors': [{'id': 'D030361', 'term': 'Papillomavirus Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D017193', 'term': 'Skin Diseases, Viral'}, {'id': 'D014412', 'term': 'Tumor Virus Infections'}, {'id': 'D012874', 'term': 'Skin Diseases, Infectious'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C402365', 'term': 'resiquimod'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'count': 88}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2004-03'}, 'statusVerifiedDate': '2006-11', 'lastUpdateSubmitDate': '2007-02-16', 'studyFirstSubmitDate': '2005-06-20', 'studyFirstSubmitQcDate': '2005-06-20', 'lastUpdatePostDateStruct': {'date': '2007-02-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2005-06-21', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Clearance of treated common wart(s)'}], 'secondaryOutcomes': [{'measure': 'Partial clearance of treated common wart(s)'}, {'measure': 'Wart recurrence'}]}, 'conditionsModule': {'keywords': ['Wart(s)', 'Adults', 'Common Wart(s)'], 'conditions': ['Warts']}, 'descriptionModule': {'briefSummary': 'The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks.\n\nA second purpose is to evaluate the safety of the drug.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnosis of common warts\n* Two forms of birth control\n\nExclusion Criteria:\n\n* Pregnant or breast feeding\n* Other types of wart(s), ie. plantar\n* Currently participating in another clinical study\n* Chronic viral hepatitis B or C'}, 'identificationModule': {'nctId': 'NCT00114920', 'briefTitle': 'Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults', 'organization': {'class': 'INDUSTRY', 'fullName': 'Graceway Pharmaceuticals, LLC'}, 'officialTitle': 'A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults', 'orgStudyIdInfo': {'id': '1508-RESI'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Resiquimod', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'zip': '47713', 'city': 'Evansville', 'state': 'Indiana', 'country': 'United States', 'facility': 'Welborn Clinic', 'geoPoint': {'lat': 37.97476, 'lon': -87.55585}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Graceway Pharmaceuticals, LLC', 'class': 'INDUSTRY'}}}}